Canada vs Georgia: Access to anti-retroviral drugs, female
Canada
72.0%
in 2022
Georgia
72.0%
in 2024
Canada rank
76th
Georgia rank
76th
Access to anti-retroviral drugs, female over time
- Canada
- Georgia
How they compare
Canada currently reports 72.0% against 72.0% in Georgia, a difference of 0.0%.
The two have swapped places 3 times across 23 shared years of data; in 2000 it was Canada ahead.
Canada ranks 76th and Georgia ranks 76th of 141 countries.
Across the 3 decades both report, Canada averaged higher in 2 and Georgia in 1.
Head to head by decade
| Decade | Canada | Georgia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 26.2% | 12.0% | 14.2% | Canada |
| 2010s | 62.6% | 62.0% | 0.6% | Canada |
| 2020s | 73.7% | 75.7% | 2.0% | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Canada or Georgia?
- Canada, at 72.0% against 72.0% in Georgia as of 2022.
- What is the difference in access to anti-retroviral drugs, female between Canada and Georgia?
- 0.0%, with Canada ahead.
- How many years of comparable data are there for Canada and Georgia?
- 23 years are reported by both, from 2000 to 2022.
- How do Canada and Georgia rank globally for access to anti-retroviral drugs, female?
- Canada ranks 76th and Georgia ranks 76th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.